Know Labs, Inc. (NYSE American: KNW), a trailblazer in the development and application of radio frequency dielectric spectroscopy (RFDS), is excited to unveil the creation of its new business unit, Know Labs Technology Licensing (KTL). Drawing inspiration from the successful Qualcomm Technology Licensing (QTL) model, KTL will focus on licensing Know Labs’ extensive intellectual property (IP) portfolio to corporate partners, academic institutions, and research organizations. This initiative aims to drive innovation and accelerate the widespread adoption of RFDS platform technology across various industries, as well as within the academic and scientific communities.
Know Labs, Inc. (NYSE American: KNW), a leader in the development of radio frequency dielectric spectroscopy (RFDS) technology, has taken a significant step in its growth strategy with the launch of a new business unit, Know Labs Technology Licensing (KTL). This strategic move marks a pivotal moment in the company’s mission to not only revolutionize medical diagnostics but also bring its groundbreaking RFDS technology to a broader array of industries, including automotive, industrial processes, consumer electronics, and the Internet of Things (IoT).
While Know Labs remains primarily focused on transforming non-invasive medical diagnostics, particularly in blood glucose monitoring, the creation of KTL enables the company to license its cutting-edge RFDS platform to external partners across multiple sectors. This new business unit is expected to unlock untapped value, allowing Know Labs to expand its reach beyond healthcare into areas that can benefit from RFDS technology’s precision and capabilities.
Amplifying Reach Through Strategic Licensing
“The formation of KTL is a bold step forward for Know Labs,” said Ron Erickson, CEO and Chairman of Know Labs. “It positions us not only as a leader in patent licensing for advanced RF spectroscopy technology but also as a catalyst for collaborative innovation that extends far beyond the realm of medical diagnostics. The sheer scope of opportunities has made it clear that we must embrace an open collaboration model with both corporate partners and top-tier academic institutions.”
Erickson’s vision for KTL goes beyond licensing deals. By opening up the RFDS platform to other industries, the company aims to foster innovation across diverse sectors while advancing the adoption of RFDS as an industry standard. “We are excited about the possibilities of RFDS technology being used in applications ranging from industrial processes to consumer electronics,” he continued. “By collaborating with industry leaders and research organizations, we can accelerate the development of real-world solutions with a significant impact.”
Building on Past Successes and New Partnerships
The creation of KTL follows the company’s earlier announcement in May 2024 about the formation of a Skunkworks initiative, aimed at exploring the application of RFDS technology beyond medical diagnostics. Erickson noted that the response from third parties expressing interest in the RFDS platform exceeded expectations, prompting the establishment of KTL as a structured and streamlined pathway for licensing partnerships.
“We were pleasantly surprised by the overwhelming interest in exploring the use of RFDS technology outside of medical diagnostics,” said Erickson. “This demand led us to establish KTL, ensuring we have a cohesive and efficient approach to working with partners. A prime example of this is our collaboration to develop a ‘smart steering wheel’ designed to improve safety in the automotive sector, which will enhance Know Labs’ leadership in automotive medical IoT sensors.”
In addition to the automotive sector, Know Labs sees RFDS technology as a highly sensitive “change or difference detector,” offering applications in a variety of industrial processes. With this in mind, the company plans to partner with academic institutions and research organizations to commercialize RFDS-based data collection and application development platforms for clinical research. Know Labs intends to provide Software Development Kits (SDKs) and a suite of RFDS test automation products to its licensing partners, further expanding the technology’s potential uses.
Dual Focus: Generating Revenue and Driving Adoption
KTL will operate with a dual mission: first, to monetize Know Labs’ extensive intellectual property (IP) portfolio by generating licensing revenue, and second, to accelerate the adoption of RFDS technology across industries. This approach aligns with Know Labs’ broader goal of creating value for shareholders while advancing technologies that solve real-world challenges. Importantly, KTL is a direct response to the growing, unsolicited demand from external parties eager to explore the potential of RFDS technology.
Expanding the Reach of RFDS Technology
Know Labs’ RFDS platform uses radio frequency spectroscopy to direct electromagnetic energy through a substance or material, capturing a unique molecular signature. The technology is adaptable, designed to be integrated into a range of form factors such as wearable devices, mobile devices, or bench-top instruments. Know Labs believes that this patented and patent-pending technology can revolutionize industries by offering non-invasive, accurate, and affordable monitoring of substances or analytes that were previously only detectable through invasive or costly lab-based tests.
The company’s flagship product, a non-invasive glucose monitor, is one of the first applications expected to come to market. This product aims to provide users with real-time, accessible, and affordable blood glucose readings. However, this product will require U.S. Food and Drug Administration (FDA) approval before it can be launched. In contrast, other products developed through KTL may not need FDA approval, allowing for a potentially faster route to market.
